Flatiron Health will incorporate comprehensive genetic testing from precision medicine firm Tempus AI directly into its cloud-based electronic medical record (EMR) platform, allowing providers in Flatiron's network to receive results directly from Tempus through Flatiron's molecular profiling integration (MPI).
With the integration of Tempus' molecular profiling capabilities into the MPI, a two-way system between labs and Flatiron's OncoEMR platform, 4,200 providers at more than 800 community-based cancer care facilities across the U.S. can order and track testing and receive test results directly within the platform.
The integration will give Flatiron's providers access to Tempus tests, including xT, xR, xF/xF+, xG/xG+ Ambry, and xM/xM (NeXT Personal Dx), as well as several of Tempus' add-on artificial intelligence-enabled tests. The integration will include a single order form to be deployed across all MPI-participating practices, which will streamline the process and ensure consistency, according to the companies.
